Literature DB >> 2932902

Primary angiographic success rates of percutaneous transluminal coronary angioplasty.

H V Anderson, G S Roubin, P P Leimgruber, J S Douglas, S B King, A R Gruentzig.   

Abstract

Three distinct periods in catheter design have been identified since the advent of percutaneous transluminal coronary angioplasty (PTCA) in 1977. In the first period PTCA was performed using a double-lumen balloon catheter that had a fixed, flexible guidewire at the tip. In the second period, an independent, steerable guidewire and the steerable catheter system were used. In the third period, low-profile catheters were introduced. A total of 2,969 patients who had single-vessel PTCA of a native coronary artery was separated into groups according to the period during which PTCA was performed. Introduction of the steerable catheter system was accompanied by improvement in primary success rate in PTCA attempts on the right coronary artery (78% vs 88%, p less than 0.005). Introduction of the low-profile catheter was accompanied by improved primary success in PTCA attempts on the left anterior descending coronary artery (LAD) (90% vs 94%, p less than 0.005). The percentage of PTCA attempts on the LAD decreased over the 3 periods (70% to 60% to 56%), while the percentage of attempts on the left circumflex artery increased (7% to 12% to 16%). Before steerable and low-profile catheters were used, there were significant differences in ability to reach and cross stenoses among the 3 major coronary arteries. These differences no longer exist. These results indicate that technical improvements and operator experience have made stenoses in all 3 major coronary arteries equally accessible to dilatation catheters and that primary success rates and reasons for failure in these arteries are now similar.

Entities:  

Mesh:

Year:  1985        PMID: 2932902     DOI: 10.1016/0002-9149(85)91121-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Arterial stenting with self-expandable and balloon-expandable endoprostheses.

Authors:  W J van der Giessen; P W Serruys; L J van Woerkens; K J Beatt; W J Visser; J F Jongkind; R H van Bremen; E Ridderhof; H van Loon; L K Soei
Journal:  Int J Card Imaging       Date:  1990

2.  The Feasibility and Safety of Same-Day Discharge for All Comers after Elective Percutaneous Coronary Interventions.

Authors:  Ali Hama Amin; Fahad Alqahtani; Sami Aljohani; Peter Farjo; Kinjan Patel; Akram Kawasra; Annina Guzek; Mohamad Alkhouli
Journal:  Cardiovasc Revasc Med       Date:  2019-10-23

3.  Assessing the success of percutaneous transluminal coronary angioplasty.

Authors:  P D Bourdillon
Journal:  Br Heart J       Date:  1987-09

Review 4.  Percutaneous transluminal coronary angioplasty: state of the art and future directions.

Authors:  G S Roubin; A R Gruentzig
Journal:  Int J Card Imaging       Date:  1985

Review 5.  Coronary angioplasty.

Authors:  I C Cooper; M Signy; M M Webb-Peploe; D J Coltart
Journal:  Postgrad Med J       Date:  1987-05       Impact factor: 2.401

6.  Percutaneous coronary angioplasty: technique, indications, and results.

Authors:  G S Roubin; A R Gruentzig; W J Casarella
Journal:  Cardiovasc Intervent Radiol       Date:  1986       Impact factor: 2.740

7.  Emergency coronary artery bypass surgery for failed percutaneous coronary angioplasty. A 10-year experience.

Authors:  J M Craver; W S Weintraub; E L Jones; R A Guyton; C R Hatcher
Journal:  Ann Surg       Date:  1992-05       Impact factor: 12.969

8.  Short term results of percutaneous transluminal coronary angioplasty with the monorail technique: experience in the first 1000 patients.

Authors:  P J de Feyter; P W Serruys; M van den Brand; H Suryapranata; K Beatt
Journal:  Br Heart J       Date:  1990-04

Review 9.  Indications for coronary angioplasty in acute myocardial ischemic syndromes.

Authors:  P J de Feyter; P W Serruys; P G Hugenholtz
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.